4786-76-9

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrrolo[2,3-d]pyrimidine, 4-methoxy(8CI,9CI) is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to contribute to the development of new drugs. Its unique structure allows for the creation of molecules with potential therapeutic properties, making it valuable in drug discovery and medicinal chemistry research.
Used in Organic Synthesis:
In the field of organic synthesis, 1H-Pyrrolo[2,3-d]pyrimidine, 4-methoxy(8CI,9CI) is utilized as a building block for the construction of complex organic molecules. Its presence in synthetic pathways can lead to the formation of a variety of bioactive compounds, broadening the scope of chemical entities that can be explored for potential applications.
Used in Medicinal Chemistry Research:
1H-Pyrrolo[2,3-d]pyrimidine, 4-methoxy(8CI,9CI) is employed as a subject of study in medicinal chemistry to investigate its pharmacological activities. Researchers are interested in exploring its potential therapeutic applications, given its structural attributes that may confer beneficial biological effects.
Used in Drug Discovery:
As a component in drug discovery processes, 1H-Pyrrolo[2,3-d]pyrimidine, 4-methoxy(8CI,9CI) is used to identify and optimize lead compounds. Its incorporation into various chemical libraries aids in high-throughput screening efforts to find new therapeutic agents with desired properties.

InChI:InChI=1/C7H7N3O/c1-11-7-5-2-3-8-6(5)9-4-10-7/h2-4H,1H3,(H,8,9,10)

Upstream product

• 67-56-1 methanol 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1196662-03-9 5-iodo-4-methoxy-7H-pyrrolo[2,3-d]pyrimidine 
• 1168106-60-2 5-bromo-4-methoxy-7H-pyrrolo[2,3-d]pyrimidine 
• 1316228-35-9 C₂₁H₂₂N₆O₃ 
• 1316228-58-6 5-(1-benzyl-1H-1,2,3-triazol-4-yl)-4-methoxy-7H-pyrrolo[2,3-d]pyrimidine 

Relevant academic research and scientific papers

NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7

Compounds of formula (I): wherein R1, R2, R3, B, W, Z, m and n are as defined in the description The compounds of the present invention have pro-apoptotic and/ or anti-proliferative properties making it possible to use the

THERAPEUTIC INHIBITORY COMPOUNDS

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

NEW (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I):wherein R1, R2, J, K, L, n and W are as defined in the description. Medicaments.

NEW PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I) wherein R1, R2, R3, n and W are as defined in the description. Medicaments.

Synthesis and Anti-HCV Activity of 4-Methoxy-7H-Pyrrolo[2,3-d] Pyrimidine Carbocyclic Nucleosides

The present study includes the exploration of new possible nucleoside mimetics based on 4-methoxy-7H-pyrrolo[2,3-d]pyrimidine carbocyclic nucleosides (4a–g), which were synthesized by 10–15 synthetic steps and characterized adequately. We report the anti-

COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR

Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR

Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof derivatives thereof, forms thereof are active on at least one Raf protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Raf protein kinases, including melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease.

COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR

Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereo